Moderna Stock News

Moderna Inc. (NASDAQ: MRNA ) shares are trading higher Monday after the company said it expects FY21 product sales of approximately $17.5 billion. Throughout 2021 the company shipped approximately 807 million doses of the Moderna COVID-19 vaccine. About 25% of all doses went to low and middle income countries through direct sales by Moderna and donations from high income countries. Moderna was up 8.25% at $231.53 at the time of publication. Moderna Daily Chart Analysis The price looks to have climbed back higher and is sitting slightly above the higher low trendline again. If the higher low trendline ends up holding as an area Full story available on Benzinga.com

These are the stocks posting the largest moves in midday trading.

The latest estimates from the CDC say the Omicron variant accounts for about 95% of all current COVID-19 cases in the US.

Moderna CEO Stephane Bancel said the omicron specific booster will enter clinical trials soon.

Moderna (MRNA) and Carisma Therapeutics have entered into a strategic collaboration agreement to discover, develop and commercialize in vivo engineered chimeric antigen receptor

Collaboration will combine Carisma''s engineered macrophage technology with Moderna''s mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration funded by Moderna with options for up to twelve targets Carisma to receive $45 million up-front cash payment and investment by Moderna…

During its third-quarter earnings results report, Moderna said commercial booster market sales could be up to $2 billion in the United States in 2022.

High-flying tech and growth stocks were among the most popular Full story available on Benzinga.com

COVID Vaccines Do Disrupt Menstrual Cycles, New Study Reveals Authored by Zachary Stieber via The Epoch Times (emphasis ours), A COVID-19 vaccine is administered in Orange, Calif., on Dec. 16, 2020. (John Fredicks/The Epoch Times) Getting a COVID-19 vaccine has been linked to a change in the menstrual cycle among women, per a new study. Dr. Alison Edelman of the Oregon Health & Science University and other researchers studied cycles among 2,403 vaccinated and 1,556 unvaccinated women and concluded vaccination was associated with a change in cycle length. The change was pegged at under one day; no change in menses length was detected. Researchers said that vaccines that use messenger RNA technologyboth Pfizers and Modernas dotrigger an immune response, which could temporarily affect the hypothalamic-pituitary-ovarian axis function, and the study results support the hypothesis. Our findings are reassuring; we find no population-level clinically meaningful change in menstrual cycle length associated with COVID19 vaccination.

The U.S. company Moderna has donated 2.7 million doses of coronavirus vaccine to Mexico as the country''s official death toll topped 300,000

Moderna CEO Scrambles To Sell More Boosters As Omicron Wave Shows Signs Of Waning While the rest of the world rejoices at the possibility that the omicron wave might actually bring about the end of the pandemic (while also being bullish for stocks, as we explored earlier in a post about some recent findings out of South Africa ), vaccine makers are already strategizing about how they will convince the world to keep buying boosters when the imminent threat posed by COVID has receded. Speaking at a conference hosted by - who else? - Goldman Sachs, Moderna CEO Stephane Bancel said another round of vaccine boosters will probably be needed this fall, even if immunity to the rapidly spreading omicron does become widespread, like the South African scientists have warned. Bancel added that even if omicron finally causes COVID to become endemic, there will still be a need for people to get their shots, since it''s not clear how long the current wave of immunity will hold. And there''s always uncertainty, since noboody can say for sure what future iterations of SARS-CoV-2 will be like. "Assuming omicron is an acceleration to the endemic phase, I still believe we''re going to need boosters in the fall of 22 and forward," Bancel said during his presentation.

This question could make or break the stock in the years ahead.

Moderna''s CEO Stephane Bancel says its mRNA platform ''can be the answer to a lot of problems.

Amazon.com, Inc (NASDAQ:AMZN), Moderna, Inc